Instil Bio Q2 net loss narrows on lower R&D spending, restructuring charges

Instil Bio

13/08/2026 22:10

Overview
U.S. biotech firm's Q2 net loss and operating expenses declined sharply yr/yr
Company ended Q2 with $69.9 mln cash, expected to fund operations beyond 2027
Instil is evaluating potential acquisitions and in-licensing of novel therapeutic candidates

Outlook
Company expects current cash position to fund operations beyond 2027

Result Drivers
LOWER R&D SPENDING - Co attributed reduced operating expenses to lower research and development costs
REDUCED RESTRUCTURING CHARGES - Decline in restructuring and impairment charges contributed to lower net loss
NO IN-PROCESS R&D EXPENSES - Co reported nil in-process research and development expenses in Q2 2026

Company press release: ID:nGNX6pjhST

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$4.30 mln
 
Q2 Loss Per Basic Share
 
$0.63
 
Q2 Operating Expenses
 
$5.58 mln
 
Q2 Operating Income
 
-$5.58 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Instil Bio, Inc. is $7.00, about 6.4% below its August 12 closing price of $7.48

Reuters Recommended Reads
Aug 13 - Elicio Therapeutics Q2 net loss narrows as R&D expenses fall
Aug 12 - AEON Biopharma Q2 net loss narrows on warrant gain; cash runway extended
Aug 13 - Assembly Biosciences Q2 net loss narrows as revenue rises

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)